GLP-1RA use necessitated shifting priorities in nutrition and lifestyle modification among patients with obesity, according ...

China-based MindRank’s oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved up to 10.5% weight loss in a ...

GLP-1RA use initially lowered delirium risk but eventually heightened delirium risk after 5 years among patients with type 2 diabetes.

Israel: A new study published in JAMA Network Open highlights a key safety insight for patients with type 2 diabetes taking ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...

Over 100 cases of acute pancreatitis have been reported to UK health regulators this year, many tied to the newest GLP-1 drug ...

Geneva: The World Health Organization (WHO) has issued a global safety alert highlighting the risk of non-arteritic anterior ...

MDR-001 represents MindRank’s lead asset and the first AI-designed oral GLP-1RA to report positive Phase 2b data globally. These results lay a solid foundation for late-stage development and future ...

Multimodal AOMs were associated with the highest preoperative weight loss among patients with high BMI undergoing bariatric surgery.

Verdiva Bio to Present New Data Highlighting Once-Weekly Potential of Its Investigational Oral Obesity Candidates at the ADA ...

An analysis of 1.7 million patients shows semaglutide may significantly reduce Alzheimer and vascular dementia risk compared ...